Form 10-K OCULAR THERAPEUTIX, INC For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Ocular Therapeutix (OCUL) PT Lowered to $17 at BofA Securities, PT $17
March 3, 2025 11:48 AM ESTBofA Securities analyst Tazeen Ahmad lowered the price target on Ocular Therapeutix (NASDAQ: OCUL) to $17.00 (from $18.00) while maintaining a Buy rating.
The analyst comments "Ocular (OCUL) reported an amendment to the SPA for SOL-1 to include re-dosing at weeks 52 and 76. Mgmt underscored the 9-month... More
